AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02230904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine (Test product PR 2.3.1)
Description: * Pharmaceutical form: Transdermal patch~* Concentration: 8 mg/24 hours~* Route of administration: Transdermal
Study NCT02230904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine (Reference product PR 2.1.1)
Description: * Pharmaceutical form: Transdermal patch~* Concentration: 8 mg/24 hours~* Route of administration: Transdermal
Study NCT01093729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM11260C
Description: HM11260C 0.5mcg/kg or Placebo
Study NCT04163120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low calorie Mediterranean ketogenic diet with phytoextracts (KEMEPHY)
Description: The KEMEPHY diet (24-29) is a Mediterranean low calories ketogenic protocol (about 1000/1100 Kcal/day) with the use of some phytoextracts. During this protocol subjects are allowed to eat with no limits green leafy vegetables, cruciferous, zucchini, cucumbers and eggplants. The quantity of meat, eggs and fish was limited to once a day (120g of meat or 200g of fish or 1 egg) Table 1. Moreover, subjects daily consumed four food supplements and liquid herbal extracts. Food supplements are high proteins (19g/portion) and very low carbohydrate (3.5g/portion) formulas simulating the aspect and taste of common carbohydrate rich foods added with dry phytoextracts (30). Liquid herbal extracts were used for their draining /toning activity, useful to reduce some commonly reported light side effects of ketogenic diets as constipation, headache and halitosis.
Study NCT03952273 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PCI with BioMatrix Alpha™ stent
Description: Randomozation between either Sirolimus eluting and endothelial progenitor cell Combo™ stent or Biolimus eluting absorbable polymer coated BioMatrix Alpha™ stent
Study NCT03952273 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PCI with Combo™ stent
Description: Randomozation between either Sirolimus eluting and endothelial progenitor cell Combo™ stent or Biolimus eluting absorbable polymer coated BioMatrix Alpha™ stent
Study NCT06578026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience Builder Program
Description: The Resilience Builder Program® group therapy will meet for one class period once a week during the semester (12 sessions). The group aims to improve resilience skills: areas such as the ability to control emotions and behavior, social skills and interactions with peers, problem-solving skills, ability to be flexible in different situations, self-esteem, and optimistic thinking. The groups involve the group leader presenting a new topic and skill, the students discussing this topic and developing strategies associated with the skill, the students practicing the skill while getting feedback from the group leader, and a period focused on self-control strategies. A letter reviewing each session will be sent home to the parent/guardian each week. Also, each child will be asked to do an assignment between weekly sessions to help him/her practice new skills.
Study NCT01332760 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: narrow diameter heavy dental tool
Description: 8mm diameter, heavy periodontal tool made from steel
Study NCT01093729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM11260C
Description: HM11260C 2mcg/kg or Placebo
Study NCT05872984 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: adjustment of dry weight based on absolute blood volume measurement
Description: adjustment of dry weight based on absolute blood volume measurement
Study NCT01110161 — intervention group
Intervention type: DEVICE
Intervention: Visceral fat mass measurement
Description: Total body DXA measurement, Abdominal CT scan
Study NCT01332760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: large diameter light weight tool
Description: Periodontal tools (4-8) provided to dental practitioners to use for all dental scaling or cleaning. This tool handle diameter is 11 mm diameter and it is made from lightweight Delrin.
Study NCT04129957 — intervention group
Intervention type: PROCEDURE
Intervention: Placement of dental implants
Description: All the included patients underwent the placement of at least one implant in either upper jaw, or lower jaw, or both.
Study NCT00675363 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Protocolized Sedation
Description: Nurse-directed protocol for administering sedation and/or analgesia.
Study NCT00675363 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Protocolized sedation, with daily interruption
Description: Nurse-directed protocols for administering sedation and/or analgesia, with daily interruption of sedation/analgesia
Study NCT03617380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: patients participating Usual Care discharge services
Study NCT01093729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM11260C
Description: HM11260C 4mcg/kg or Placebo
Study NCT01093729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM11260C
Description: HM11260C 8mcg/kg or Placebo
Study NCT03617380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PharmD TOC
Description: patients participating in a community pharmacy-based Transitions of Care Program (PHARMD-TOC)
Study NCT03822585 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CBC, Iron Study, Serum Ferrittin, HPLC,Genitic Study
Description: high performance liquid chromatography (HPLC) has become the preferred technique, as it can detect most of the clinically significant variants. polymerase chain reaction (PCR)-based procedures detect Commonly occurring mutations of the HBB gene .~If targeted mutation analysis fails to detect the mutation, scanning or sequence analysis can be used. Sensitivity of both mutation scanning and sequence analysis is 99%.
Study NCT01093729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM11260C
Description: HM11260C 14mcg/kg or Placebo
Study NCT01037920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-affirmation exercise
Description: The intervention exercise asks subjects to reflect on a list of 11 personal values and to circle 2 or 3 items that are most important to them. Subjects are asked then to write a few sentences to describe why they are important.
Study NCT01037920 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control exercise is the same as the intervention exercise except that subjects reflect and write about values important to someone else.
Study NCT00838110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: 10 mg TID for week 1 followed by 20 mg TID through Week 26
Study NCT00838110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mg TID for week 1 followed by 20 mg TID through Week 26
Study NCT00838110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: 10 mg TID for week 1 followed by 20 mg TID through Week 12
Study NCT00838110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mg matched Placebo (Cohort 2) 10 mg TID for week 1 followed by 20 mg TID through Week 12
Study NCT04897958 — intervention group
Intervention type: DRUG
Intervention: Degarelix
Description: Degarelix dispensing claim is used as the reference group.
Study NCT04897958 — intervention group
Intervention type: DRUG
Intervention: Leuprolide
Description: Leuprolide dispensing claim is used as the exposure group.
Study NCT04629911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THRIVE
Description: Patients will receive HFNO therapy during laryngomicrosurgery. Patients will undergo a gastric ultrasound examination after HFNO therapy.
Study NCT02340403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NMR Spectroscopy
Study NCT02340403 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: NMR Spectroscopy
Study NCT03742661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPEAC System
Description: Surface Electromyography (sEMG) based seizure monitoring and alerting system
Study NCT04803344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Writing tecnique
Description: Expressive Writing (EW), is a simple, potentially inexpensive, therapeutic intervention which involves writing daily for 15-20 min over 3-4 consecutive days. EW can be completed at home without the need for facilitation, a specialist therapist or a dedicated facility.
Study NCT04803344 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neutral Writing
Description: Participants were asked to write on neutral objects or events.
Study NCT01693120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Phased RF Ablation System
Description: Phased RF ablation
Study NCT03717415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebastinib
Description: Administered orally
Study NCT02151851 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: * Active substance: Certolizumab Pegol~* Pharmaceutical Form: Prefilled syringes~* Concentration: 200 mg/ml~* Route of administration: Subcutaneous injection
Study NCT02151851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: * Active substance: Methotrexate~* Pharmaceutical form: Tablet~* Concentration: Maximum dose 10 mg per week~* Route of administration: Oral
Study NCT02151851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: * Active substance: Methotrexate~* Pharmaceutical form: Tablet~* Concentration: Maximum dose 10 mg per week~* Route of administration: Oral
Study NCT02151851 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Active substance: Placebo~* Pharmaceutical form: Prefilled syringes~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous injection
Study NCT00003563 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBRT
Description: 3 GY of WBRT daily for a total of 10 days
Study NCT00003563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGd
Description: 5.0 mg /kg MGd plus WBRT
Study NCT01757184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sebelipase Alfa
Description: IV infusions of sebelipase alfa
Study NCT03717415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered by IV infusion
Study NCT01262651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabiximols
Study NCT01262651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (GA-0034)
Study NCT03281902 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT03281902 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood, urine, stool, and saliva
Study NCT03281902 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02697123 — intervention group
Intervention type: OTHER
Intervention: antepartum and postpartum
Description: This is a prospective observational cohort study.
Study NCT02489500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Conditioning Regimen:~Drug: Bortezomib: 1.0 mg/m2/dose D -6, D -3, D +1, D + 4 Drug: Melphalan: 70-100 mg/m2/dose D -2, D -1
Study NCT02489500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Conditioning Regimen:~Drug: Melphalan: 70-100 mg/m2/dose D -2, D -1 Stem Cell Transplant: D 0
Study NCT02489500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Conditioning Regimen:~Drug: Melphalan: 70-100 mg/m2/dose D -2, D -1 Stem Cell Transplant: D 0
Study NCT02489500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neupogen
Description: granulocyte colony-stimulating factor (G-CSF) mobilization 16mcg/kg x 4 days
Study NCT02489500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neupogen
Description: granulocyte colony-stimulating factor (G-CSF) mobilization 16mcg/kg x 4 days
Study NCT02489500 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stem Cell Collection
Description: collect at least 2.5 million cluster of differentiation 34 (CD34)+ stem cells
Study NCT02489500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Collection
Description: collect at least 2.5 million cluster of differentiation 34 (CD34)+ stem cells
Study NCT02489500 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stem cell infusion
Description: infusion of previously collected autologous stem cells
Study NCT02489500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Description: infusion of previously collected autologous stem cells
Study NCT00780208 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Daytrana (methylphenidate patch)
Description: Subjects will be provided with a 7-day supply of medication at each study visit. The dose will be flexible and will be titrated based on effect and tolerability. Unless a subject is experiencing side effects, the dose will be increased if a 25% reduction in ADHD symptoms as determined by the WRAADDS is not obtained. A proposed dosing schedule is as follows: Week 1: 12.5 cm2, Week 2: 18.75 cm2, Week 3: 25 cm2, Week 4: 37.5 cm2. The dose may be decreased as needed for tolerability.
Study NCT04266782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program followed by long walk in group
Description: The subjects will be included in a training exercise program for three months followed by a long-walk in group
Study NCT04266782 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program followed by long walk in group (controls)
Description: The controls matched for age will perform the same exercise program and long walk as the PD subjects
Study NCT02112214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10-day bismuth-based quadruple therapy
Description: Bismuth 300 mg (4 times a day), lansoprazole 30 mg (twice a day), metronidazole 500 mg (3 times a day), and tetracycline 500 mg (4 times a day) for 10 days
Study NCT02112214 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for bismuth-based quadruple therapy
Study NCT01757184 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusions of matched placebo
Study NCT01803750 — intervention group
Intervention type: BEHAVIORAL
Intervention: in-depth, semi-structured interviews
Description: In-depth interviews will be conducted by the Principle Investigator and will use a combination of open-ended and closed, fixed response questions. Interviews will be audio recorded if the participant agrees, and answers to fixed response questions will be marked for complete analysis. The data collection portion of the study is estimated to take approximately 8 months. Areas to be addressed in the open-ended portion of the interview include: 1) Knowledge, attitudes and beliefs toward evidence-based cancer screening and prevention approaches 2) Barriers to implementing evidence-based cancer screening practices in the individual provider's clinical setting 3) Preferences for mechanisms of information dissemination and implementation and 4) Ideas and methods to facilitate evidence-based practices to improve cancer screening in the Latino population. A community-based participatory committee (CBPC) will be formed with 5-7 key informants identified during the interview process.
Study NCT04672837 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pediatric Integrative Manual Therapy and educational therapy
Description: Pediatric Integrative Manual Therapy is a soft Orthopedic Manual Therapy approach por infants and children. It integrates joints soft mobilisation, myofascial release and neurodynamic mobilisation. Also the educational therapy.
Study NCT04672837 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stretching and educational therapy
Description: It is a protocol of stretching based on literature research. Also the educational therapy with counter positioning, stimulation in prone position, positional care, etc.
Study NCT04657029 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treadmill
Description: 30 minutes of moderate-high intensity treadmill training.
Study NCT04657029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill
Description: 30 minutes of moderate-high intensity treadmill training.
Study NCT00243126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Based Risk Reduction Intervention
Description: The intervention module topics include five modules and each module is 2 hours in length. The intervention will focus on the elements critical to HIV risk behavior change. These include: risk education (practical understanding of factors responsible for risk and behavior changes needed to reduce risk); threat personalization (accurate appraisal of personal risk based on behavior); self-efficacy (belief that one can implement risk reduction behavior changes and that if changes are made they will have protective value); skills acquisition (e.g., condom use, safer sex guidance, negotiation); cognitive problem-solving skills; and reinforcement.
Study NCT04216836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium oxide
Description: Magnesium capsule
Study NCT04216836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Cornflour capsule manufactured to mimic the 166.6 mg magnesium capsule.
Study NCT01961739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Description: Topical application, twice per day for 15 consecutive days
Study NCT01961739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: topical application, twice per day for 15 consecutive days
Study NCT04153760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81 mg
Description: Aspirin 81 mg p.o. daily
Study NCT04153760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo p.o. daily
Study NCT02175511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cloud-based home BP monitoring
Description: a sphygmomanometer-style BP measurement device (Microlife®, WatchBP Home) that stored and transmitted data to a secure cloud BP system directly via a General Packet Radio Service (GPRS) gateway through cell phone network.
Study NCT02502682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sage 2% Chlorhexidine Gluconate Cloth Patient Preoperative Skin Preparation
Description: Daily bathing.
Study NCT04277364 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: phosphatidic acid supplementation
Description: The total daily doses will be distributed in 3 individual doses: in the group that will ingest 750mg per day, the individual doses will be 250mg, while in the group that will ingest 375mg per day, the individual doses will be 125mg. The capsules should be consumed at breakfast, 30 minutes before each training session (or at lunch, on days when there is no training) and at dinner.
Study NCT04277364 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (corn starch supplementation)
Description: Three individual doses of corn starch will be consumed per day. The capsules should be consumed at breakfast, 30 minutes before each training session (or at lunch, on days when there is no training) and at dinner.
Study NCT04277364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: All participants will be submitted to a 8-week strength training program, with 3 training sessions per week, totaling 24 training sessions.
Study NCT04277364 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Strength training
Description: All participants will be submitted to a 8-week strength training program, with 3 training sessions per week, totaling 24 training sessions.
Study NCT03915587 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CardioQ-EDM and CipherOx-CRI
Description: A CardioQ-EDM probe will be placed on the day of surgery after induction of general anesthesia. The anesthesiologist will inform the investigator of plans to provide a fluid or blood bolus per clinical judgement in addition to the protocolized 10 ml/kg bolus provided after induction. While the anesthesiologist is preparing to administer volume expansion, a co-investigator will collect pre-fluid bolus data. Measurements will be recorded for data analysis at the completion of the trial. Additionally, a CipherOx-CRI probe will be placed on the patient's index finger (recorded data will be interpreted post hoc) and a bedside ultrasound will be performed by either the principal investigator (PI) or one of two co-investigators to measure the IVC CI. Ultrasound cine-loops will be recorded, and CI will be calculated post-hoc. Data will be recorded on the Data Collection Form for each fluid bolus administered. The PI and co-investigators will manage all aspects of investigational devices.
Study NCT01113437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab or placebo by subcutaneous injections, at 4 weekly or 2 weekly intervals.~Dosage is according to manufacturer's guidance and calculated based on body weight and total serum IgE.
Study NCT01113437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Omalizumab or placebo by subcutaneous injections, at 4 weekly or 2 weekly intervals.~Dosage is according to manufacturer's guidance and calculated based on body weight and total serum IgE.